Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 18, 2022 - Issue 3: The JAKi in inflammatory disorders & arthritis: lights and shadows
Submit an article Journal homepage
1,515
Views
1
CrossRef citations to date
0
Altmetric
Foreword

JAK inhibitors: special issue foreword

James Gallowaya Centre of Rheumatic Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1230-2781
ORCID Icon &
Fabiola Atzenib Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy
Pages 179-180 | Received 20 Jul 2021, Accepted 04 Feb 2022, Published online: 10 Mar 2022

References

  • Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–1421. [published Online First: 1994/06/03].
  • Haan C, Kreis S, Margue C, et al. Jaks and cytokine receptors–an intimate relationship. Biochem Pharmacol. 2006;72(11):1538–1546. [published Online First: 2006/06/06].
  • Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(Pt8):1281–1283. [published Online First: 2004/03/17].
  • Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity. 2012;36(4):503–514. [published Online First: 2012/04/24].
  • Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–1061. [published Online First: 2005/03/23].
  • Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790. [published Online First: 2005/04/29].
  • Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–2386. [published Online First: 2014/06/19].
  • Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–2524. [published Online First: 2018/06/18].
  • Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252. [published Online First: 2016/03/31].
  • Atsumi T, Tanaka Y, Matsubara T, et al. Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). Mod Rheumatol. 2021. DOI:https://doi.org/10.1093/mr/roab021. [published Online First: 2021/12/16].
  • Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383(16):1511–1521. [published Online First: 2020/10/15].
  • Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662. [published Online First: 2017/02/16].
  • McLornan DP, Pope JE, Gotlib J, et al. Current and future status of JAK inhibitors. Lancet. 2021;398(10302):803–816. [published Online First: 2021/08/30].
  • Barbulescu A, Askling J, Chatzidionysiou K, et al. Effectiveness of baricitinib and tofacitinib compared to bDMARDs in RA: results from a cohort study using nationwide Swedish register data. Rheumatology (Oxford). 2022. DOI:https://doi.org/10.1093/rheumatology/keac068. [published Online First: 2022/02/09].
  • Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326. [published Online First: 2022/01/27].
  • FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. US Food and Drug Administration; 2021.
  • EMA starts safety review of Janus kinase inhibitors for inflammatory disorders. European Medicines Agency; 2022 [ cited 2022 01 March].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.